Pro-Dex

PDEX

Market cap $138M

Pro-Dex manufactures powered surgical instruments for orthopedic, CMF, and thoracic procedures. This means that PDEX effectively combines OEM programs with a smaller catalog of industrial offerings. However, PDEX's revenue today remains highly concentrated. A single customer drives roughly 78% of sales.

Pro-Dex Inc. is a specialized surgical device manufacturer with strong growth, efficient capital allocation, and high customer concentration risk. PDEX trades at ~16x recurrent earnings, which is fair and attractive for a small, non-concentrated position given its quality and growth prospects. Customer concentration remains the key risk, but contract renewals, sticky relationships, and secular healthcare tailwinds support continued growth.

IRVINE, CA / ACCESS Newswire / December 19, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced that on December 17, 2025, it executed a contract amendment with its largest customer for an additional three years.

Pro-Dex, Inc. (PDEX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.75 per share a year ago.

IRVINE, CA / ACCESS Newswire / October 30, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2026 first quarter ended September 30, 2025.

IRVINE, CA / ACCESS Newswire / October 16, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) is issuing this press release in an effort to help avoid any confusion in the marketplace between the common stock of Pro-Dex, Inc., which trades on the Nasdaq Capital Market under the symbol PDEX, and Polkadex, which to Pro-Dex, Inc.'s understanding trades on certain crypto exchanges (and possibly on certain other platforms) under the same symbol.

Pro-Dex, Inc. (PDEX) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.46 per share a year ago.

IRVINE, CA / ACCESS Newswire / September 4, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2025 fourth quarter and full-year ended June 30, 2025.

ProDex (PDEX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

NGD, GECC, MITSY, CWEN and PDEX have been added to the Zacks Rank #1 (Strong Buy) List on July 1, 2025.